MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/blood-2018-01-826008

Медицинская библиотека · Blood · 2018

High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies.

Dreger Peter, Ghia Paolo, Schetelig Johannes, van Gelder Michel, Kimby Eva, Michallet Mauricette, Moreno Carol, Robak Tadeusz, Stilgenbauer Stephan, Montserrat Emili, European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT)

СтатьяОбзорПеревод в очереди

Аннотация

High-risk chronic lymphocytic leukemia (CLL) has been defined by clinical and/or genetic resistance (TP53 abnormalities) to treatment with chemoimmunotherapy (CIT). With the availability of pathway inhibitors (PIs), such as kinase inhibitors and BCL2 antagonists, the outlook of CIT-resistant patients has dramatically improved. Here, we propose a revision of the concept of high-risk CLL, driven by TP53 abnormalities and response to treatment with PI. CLL high-risk-I, CIT-resistant is defined by clinically CIT-resistant disease with TP53 aberrations, but fully responsive to PI. This category is largely the domain of PI-based therapy, and cellular therapy (ie, allogeneic hematopoietic cell transplantation) remains an option only in selected patients with low individual procedure-related risk. In CLL high-risk-II, CIT- and PI-resistant, characterized by increasing exhaustion of pharmacological treatment possibilities, cellular therapies (including chimeric antigen receptor-engineered T cells) should be considered in patients eligible for these procedures. Moreover, molecular and cellular therapies are not mutually exclusive and could be used synergistically to exploit their full potential.

Для цитирования: Dreger Peter, Ghia Paolo, Schetelig Johannes, van Gelder Michel, Kimby Eva, Michallet Mauricette, Moreno Carol, Robak Tadeusz, Stilgenbauer Stephan, Montserrat Emili, European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT). High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies.. Blood. 2018. DOI: 10.1182/blood-2018-01-826008.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.